Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

The Prognostic Significance of Minimal Residual Disease in Multiple Myeloma in the Molecular Genetic Groups Msmart 3.0

Andrey Garifullin, MD, Sergei Voloshin, MD PhD, Sergey Linnikov, Irina Martynkevich, MD PhD, Alexey Kuvshinov, MD, Anastasiya Kuzyaeva, Zhanna Chubukina, Vasily Shuvaev, MD, Elizaveta Kleina, Marina Bakai, Alexander Sсhmidt

Blood (2020) 136 (Supplement 1): 42.

https://doi.org/10.1182/blood-2020-139239

Published: 2020

Journal Articles

The Comparison of Results of Autologous Transplantation Using Non-Cryopreserved and Cryopreserved Hematopoietic Stem Cells (HSC)

Sergei Voloshin, MD PhD, Andrey Garifullin, MD, Sergey Linnikov, Anastasiya Kuzyaeva, Vasily Shuvaev, MD, Valentina Balashova, Georgiy Rysev, MD, Alexander Chechetkin, MD PhD, Zanna Chebukina

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-142279

Published: 2020

Journal Articles

Short-Term Noncryopreserved Hematopoietic Stem Cells: Single Center Experience of Autologous Transplantation

Sergei Voloshin, MD PhD, Andrey Garifullin, MD, Anastasiya Kuzyaeva, Vasily Shuvaev, MD, Alexander Schmidt, Alexey Kuvshinov, MD, Valentina Balashova, Zhanna Chubukina, Elena Belyakova, MD, Georgiy Rysev, MD, Alexander Chechetkin, Viktor Rugal'

Blood (2019) 134 (Supplement_1): 5636.

https://doi.org/10.1182/blood-2019-131695

Published: 2019

Journal Articles

Significance of Modified Risk Stratification Msmart 3.0 and Autologous Stem Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma

Andrey Garifullin, MD, Sergei Voloshin, MD PhD, Vasily Shuvaev, MD, Irina Martynkevich, MD PhD, Elizaveta Kleina, Alexander Chechetkin, Stanislav Bessmeltcev, Anastasiya Kuzyaeva, Alexander Sсhmidt, Alexey Kuvshinov, MD, Irina Pavlova

Blood (2019) 134 (Supplement_1): 5593.

https://doi.org/10.1182/blood-2019-130092

Published: 2019

Journal Articles

Maintenance Therapy in Patients with Chronic Lymphocytic Leukemia Who Achieved MRD-Positive Remissions after Induction Therapy

Alexey Kuvshinov, MD, Sergei Voloshin, MD PhD, Vasily Shuvaev, MD, Elena Belyakova, MD, Mariia Mikhaleva, MD, Andrey Garifullin, MD, Georgiy Rysev, MD, Alexander Bogdanov, MD PhD, Irina Martynkevich, MD PhD, Elizaveta Kleina, Alena Samorodova, MD, Iuliia Ruzhenkova, Iuliia Vokueva, Alexander Chechetkin

Blood (2019) 134 (Supplement_1): 5475.

https://doi.org/10.1182/blood-2019-129995

Published: 2019

Journal Articles

Russian Experience of Bosutinib Use in Chronic Myeloid Leukemia Patients in Routine Clinical Practice

Vasily Shuvaev, MD, Olga Vinogradova, MD PhD, Irina Martynkevich, MD PhD, Novitskaya Natalya, MD, Mikhail Fominykh, MD, Svetlana Tsareva, Dzhariyat Shikhbabaeva, Maria Pankrashkina, Mikhail Chernikov, Nikolay Sharkunov, MD PhD, Irina Zotova, MD, Vera Udaleva, MD PhD, Ekaterina Motyko, MD, Sergei Voloshin, MD PhD

Blood (2018) 132 (Supplement 1): 5446.

https://doi.org/10.1182/blood-2018-99-114164

Published: 2018

Journal Articles

Role of Molecular Drivers in Coagulation By Integral Assessment in Primary Myelofibrosis Patients

Elizaveta Efremova, MD, Olesya Matvienko, MD, Natalya Korsakova, Mikhail Fominykh, MD, Natalya Silina, Ludmila Papayan, Lyubov Polushkina, MD, Ekaterina Motyko, MD, Irina Martynkevich, MD PhD, Vasily Shuvaev, MD, Sergei Voloshin, MD PhD

Blood (2018) 132 (Supplement 1): 5473.

https://doi.org/10.1182/blood-2018-99-118801

Published: 2018

Journal Articles

Atypical Chronic Myeloid Leukemia Challenge in Russian Hematology Practice

Vasily Shuvaev, MD, Karina Krutikova, MD, Svetlana Menshakova, MD, Natalya Kalinova, MD, Irina Martynkevich, MD PhD, Lyubov Polushkina, MD, Elena Belyakova, MD, Yury Krivolapov, MD PhD, Sergei Voloshin, MD PhD

Blood (2018) 132 (Supplement 1): 5483.

https://doi.org/10.1182/blood-2018-99-114885

Published: 2018

Journal Articles

The Prognostic Significance of Minimal Residual Disease and Possibility of Its Correction in Multiple Myeloma

Andrey Garifullin, MD, Sergei Voloshin, MD PhD, Alexey Kuvshinov, MD PhD, Anastasiya Kuzyaeva, Alexander Sсhmidt, Zhanna Chubukina, Vasily Shuvaev, MD, Evgeniy Krasnikov, Sergey Linnikov

Blood (2018) 132 (Supplement 1): 5751.

https://doi.org/10.1182/blood-2018-99-118457

Published: 2018

Journal Articles

Influence of Minimal Residual Disease on Survival of Patients with Mantle Cell Lymphoma

Mariia Mikhaleva, MD, Alexey Kuvshinov, MD PhD, Alexander Schmidt, Vasily Shuvaev, MD, Karina Krutikova, MD, Elena Belyakova, Irina Martynkevich, MD PhD, Alexander Chechetkin, Sergei Voloshin, MD PhD

Blood (2018) 132 (Supplement 1): 1611.

https://doi.org/10.1182/blood-2018-99-119761

Published: 2018

Journal Articles

The Strategy of the Management of Patients with Chronic Lymphocytic Leukemia in the Post-Induction Period Based on the Results of the Evaluation of Minimal Residual Disease

Alexey Kuvshinov, MD, Sergei Voloshin, MD PhD, Vasily Shuvaev, MD PhD

Blood (2017) 130 (Supplement 1): 1732.

https://doi.org/10.1182/blood.V130.Suppl_1.1732.1732

Published: 2017

Journal Articles

The Significance of Flow Cytometry and Positron Emission Tomography and Computed Tomography (PET-CT) in the Assessment of the Minimum Residual Disease in Patients with Multiple Myeloma

Andrey Garifullin, Sergei Voloshin, MD PhD, Alexey Kuvshinov, MD, Alexander Schmidt, Vasily Shuvaev, MD PhD, Yuriy Kryvolapov, Elena Belyakova, Evgeniy Krasnikov, Alexander Chechetkin

Blood (2017) 130 (Supplement 1): 3097.

https://doi.org/10.1182/blood.V130.Suppl_1.3097.3097

Published: 2017

Journal Articles

Prognostic Impact of Distinct Combinations of Molecular Mutations in AML Patients. Results of Two-Center International Cooperation Study

Olga Blau, MD PhD, Irina Martynkevich, MD PhD, Franziska Behrenbeck, Claudia D. Baldus, MD, Ekaterina Motiko, Sergei Voloshin, MD PhD, Antonio Pezzutto, MD PhD, Bernd Dorken, MD PhD, Igor Wolfgang Blau, MD PhD

Blood (2017) 130 (Supplement 1): 5111.

https://doi.org/10.1182/blood.V130.Suppl_1.5111.5111

Published: 2017

NARROW

The Prognostic Significance of Minimal Residual Disease in Multiple Myeloma in the Molecular Genetic Groups Msmart 3.0

The Comparison of Results of Autologous Transplantation Using Non-Cryopreserved and Cryopreserved Hematopoietic Stem Cells (HSC)

Short-Term Noncryopreserved Hematopoietic Stem Cells: Single Center Experience of Autologous Transplantation

Significance of Modified Risk Stratification Msmart 3.0 and Autologous Stem Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma

Maintenance Therapy in Patients with Chronic Lymphocytic Leukemia Who Achieved MRD-Positive Remissions after Induction Therapy

Russian Experience of Bosutinib Use in Chronic Myeloid Leukemia Patients in Routine Clinical Practice

Role of Molecular Drivers in Coagulation By Integral Assessment in Primary Myelofibrosis Patients

Atypical Chronic Myeloid Leukemia Challenge in Russian Hematology Practice

The Prognostic Significance of Minimal Residual Disease and Possibility of Its Correction in Multiple Myeloma

Influence of Minimal Residual Disease on Survival of Patients with Mantle Cell Lymphoma

The Strategy of the Management of Patients with Chronic Lymphocytic Leukemia in the Post-Induction Period Based on the Results of the Evaluation of Minimal Residual Disease

The Significance of Flow Cytometry and Positron Emission Tomography and Computed Tomography (PET-CT) in the Assessment of the Minimum Residual Disease in Patients with Multiple Myeloma

Prognostic Impact of Distinct Combinations of Molecular Mutations in AML Patients. Results of Two-Center International Cooperation Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only